Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
PTCT Analyst Ratings
Moderate Buy
6 Buy
5 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PTCT Stock 12 Month Forecast
Average Price Target
$64.82
▲(17.19% Upside)
| Highest Price Target$113.00 | Average Price Target$64.82 | Lowest Price Target$50.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
Reiterated
03/20/25
J.P. Morgan
Reiterated
03/14/25
Bank of America Securities
Upgraded
03/10/25
Morgan Stanley
Initiated
03/07/25
Scotiabank
Initiated
03/07/25
Cantor Fitzgerald
Reiterated
03/03/25
Barclays
Reiterated
03/03/25
Leerink Partners
Reiterated
02/28/25
Wells Fargo
Reiterated
02/28/25
TD Cowen
$60
Hold
8.48%
Upside
Reiterated
02/27/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcellx Inc (NASDAQ: ACLX) and PTC Therapeutics (NASDAQ: PTCT)We are encouraged by the progress, and PTC enters 2025 well funded and in a strong position with several shots on goal.
RBC Capital
$63→$64
Buy
15.71%
Upside
Reiterated
02/27/25
PTC Therapeutics (PTCT) Gets a Buy from RBC Capital
Robert W. Baird
$52→$70
Buy
26.56%
Upside
Reiterated
12/03/24
PTC Therapeutics (PTCT) PT Raised to $70 at BairdBaird analyst Joel Beatty raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $70.00 (from $52.00) while maintaining a Outperform rating.
Goldman Sachs
$32→$42
Sell
-24.06%
Downside
Reiterated
12/03/24
PTC Therapeutics (PTCT) PT Raised to $42 at Goldman SachsGoldman Sachs analyst Paul Choi raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $42.00 (from $32.00) while maintaining a Sell rating.
Raymond James
―
Hold
―
Initiated
10/10/24
Raymond James resumes PTC Therapeutics (PTCT) at Market PerformRaymond James analyst Danielle Brill resumes coverage on PTC Therapeutics (NASDAQ: PTCT) with a Market Perform rating.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
Reiterated
03/20/25
J.P. Morgan
Reiterated
03/14/25
Bank of America Securities
Upgraded
03/10/25
Morgan Stanley
Initiated
03/07/25
Scotiabank
Initiated
03/07/25
Cantor Fitzgerald
Reiterated
03/03/25
Barclays
Reiterated
03/03/25
Leerink Partners
Reiterated
02/28/25
Wells Fargo
Reiterated
02/28/25
TD Cowen
$60
Hold
8.48%
Upside
Reiterated
02/27/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcellx Inc (NASDAQ: ACLX) and PTC Therapeutics (NASDAQ: PTCT)We are encouraged by the progress, and PTC enters 2025 well funded and in a strong position with several shots on goal.
RBC Capital
$63→$64
Buy
15.71%
Upside
Reiterated
02/27/25
PTC Therapeutics (PTCT) Gets a Buy from RBC Capital
Robert W. Baird
$52→$70
Buy
26.56%
Upside
Reiterated
12/03/24
PTC Therapeutics (PTCT) PT Raised to $70 at BairdBaird analyst Joel Beatty raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $70.00 (from $52.00) while maintaining a Outperform rating.
Goldman Sachs
$32→$42
Sell
-24.06%
Downside
Reiterated
12/03/24
PTC Therapeutics (PTCT) PT Raised to $42 at Goldman SachsGoldman Sachs analyst Paul Choi raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $42.00 (from $32.00) while maintaining a Sell rating.
Raymond James
―
Hold
―
Initiated
10/10/24
Raymond James resumes PTC Therapeutics (PTCT) at Market PerformRaymond James analyst Danielle Brill resumes coverage on PTC Therapeutics (NASDAQ: PTCT) with a Market Perform rating.
PTCT Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
2
1
3
3
4
Buy
11
16
16
16
13
Hold
18
21
18
12
10
Sell
5
8
7
7
5
Strong Sell
0
0
0
0
0
total
36
46
44
38
32
Each month's total comprises the sum of three months' worth of ratings.
PTCT Financial Forecast
PTCT Stock Forecast FAQ
What is PTCT’s average 12-month price target, according to analysts?
Based on analyst ratings, PTC Therapeutics’s 12-month average price target is $64.82.
What is PTCT’s upside potential, based on the analysts’ average price target?
PTC Therapeutics has 17.19% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PTCT a Buy, Sell or Hold?
PTC Therapeutics has a consensus rating of Moderate Buy which is based on 6 buy ratings, 5 hold ratings and 1 sell ratings.
What is PTC Therapeutics’s price target?
The average price target for PTC Therapeutics is $64.82. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $113.00 ,the lowest forecast is $50.00. The average price target represents 17.19% Increase from the current price of $55.31.
The highest analyst price target is $113.00 ,the lowest forecast is $50.00. The average price target represents 17.19% Increase from the current price of $55.31.
What do analysts say about PTC Therapeutics?
PTC Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of PTCT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.